Creative Biolabs develops soluble complement regulators for programs that need to restore pathway control, compare regulator architectures, build recombinant therapeutic candidates, or generate research-grade functional proteins. We support sCR1/TP10 and CR1 fragments, Factor H and mini-FH formats, C4BP, Factor I, C1 inhibitor, and custom engineered regulator constructs through sequence design, expression, purification, biophysical characterization, complement-function testing, lead optimization, and scalable material preparation.
Discuss Your Regulator Development ProjectSoluble complement regulators suppress excessive activation without relying on a single small-molecule binding pocket. Depending on the molecule, they can accelerate dissociation of C3/C5 convertases, provide cofactor activity for Factor I-mediated cleavage of C3b or C4b, restrain initiating proteases, or interfere with terminal-pathway assembly. This creates multiple engineering opportunities: preserve native multi-domain functions, isolate the domains that carry the desired activity, increase avidity, redirect the regulator to a disease-relevant surface, or extend exposure while maintaining functional specificity.
Our development service is intended for researchers working on complement-driven renal, ocular, inflammatory, autoimmune, transplant, ischemia-reperfusion, infectious-disease, and biomaterial programs, as well as teams that need recombinant regulators for mechanistic studies or assay controls. Projects can start from a published sequence, a client-owned construct, a disease-associated variant, or a design concept. We connect protein engineering with the relevant complement inhibition functional assays so each iteration is ranked by biological performance rather than expression yield alone.
We can align the soluble-regulator strategy with the pathway node, desired breadth of inhibition, matrix, and downstream assay package.
The correct soluble regulator depends on where complement must be controlled and whether the program needs broad fluid-phase inhibition, surface-focused protection, cofactor activity, or pathway-selective modulation. We can develop native-like proteins and engineered formats rather than forcing every program into the same construct.
CR1-based proteins can combine decay-accelerating and Factor I cofactor activities against C3b- and C4b-containing convertases. Programs may focus on full soluble CR1, shortened functional fragments, domain combinations, or modified constructs intended to improve potency and developability.
View sCR1/TP10 Development ServiceFactor H is central to alternative-pathway control. Candidate design can preserve host-surface recognition, concentrate regulatory domains, introduce multivalency, or combine FH segments with targeting or half-life elements. Comparative studies can include full-length FH, mini-FH architectures, variants, and fusion proteins.
Explore Factor H DevelopmentC4BP regulates classical- and lectin-pathway convertases and provides Factor I cofactor activity. Development can address alpha-chain composition, multimeric assembly, recombinant expression, purification behavior, C4b/C3b interaction, and functional preservation in pathway-specific assays.
View C4BP Development ServiceFactor I is a cofactor-dependent serine protease, so development cannot be judged by expression and purity alone. We can compare wild-type, variant, recombinant, or engineered Factor I through substrate cleavage in the presence of appropriate cofactors such as Factor H, C4BP, CR1, or membrane-associated partners.
Explore Factor I DevelopmentC1-INH regulates initiating proteases of the classical and lectin pathways. Development studies can address recombinant or modified C1-INH, protein integrity, glycosylation-sensitive expression, protease-inhibitory function, stability, and pathway-level suppression in complement-containing matrices.
View C1-INH Functional TestingFor project-defined mechanisms, we can evaluate soluble ectodomains or engineered regulatory modules derived from CD46, CD55, CD59, clusterin, vitronectin, or other complement-control proteins, as well as targeted fusions that localize regulation to a cell, matrix, pathogen, nanoparticle, or tissue-associated ligand.
Explore Complement RegulatorsA soluble regulator is often a multi-domain glycoprotein whose biological function depends on architecture and context. We therefore treat construct design, expression behavior, biophysical quality, and complement function as connected variables.
Map known regulatory and recognition regions, remove dispensable sequence where appropriate, compare domain boundaries, and combine modules that retain the required C3b/C4b interaction, cofactor activity, decay acceleration, or surface-recognition properties.
Introduce dimerization or multivalent arrangements when increased avidity, local retention, or functional density may improve inhibition. Candidate selection can compare monomeric and multimeric designs under the same complement conditions.
Fuse regulatory domains to Fc, albumin-binding elements, receptor- or ligand-targeting modules, or other project-defined partners to tune exposure or concentrate activity at a relevant biological surface while monitoring unwanted complement effects from the fusion scaffold.
Sequence optimization, signal-peptide selection, host choice, secretion screening, stable or transient expression, and culture-condition optimization are used to improve yield while preserving folding, disulfide pairing, assembly, and glycosylation-dependent quality.
Compare variants for aggregation, fragmentation, thermal or storage stability, freeze-thaw tolerance, concentration behavior, and buffer compatibility. Engineering cycles can address exposed hydrophobic regions, labile junctions, or architecture-driven instability.
Disease-associated alleles, loss- or gain-of-function variants, binding-site substitutions, linker changes, and client-designed mutations can be produced in parallel to connect molecular changes with complement regulatory activity.
Large RCA-family proteins and C1-INH often benefit from eukaryotic secretion systems because domain folding, disulfide formation, multimeric assembly, or glycosylation can affect product quality. HEK293 or CHO-based expression is therefore a common starting point for many therapeutic-style constructs, while alternative systems can be evaluated for research applications or specific manufacturing strategies.
Rather than applying a fixed platform, we select the host and purification approach according to molecular architecture, required scale, downstream functional assay, and whether the material is intended for screening, mechanistic work, or further preclinical development.
We can start with expression rescue, side-by-side variant production, or functional ranking without rebuilding the program from the beginning.
Functional characterization is designed around the expected mechanism. Orthogonal assays can separate binding from regulatory activity, identify pathway breadth, and show whether potency observed in purified systems is retained in serum or cell-based environments.
| Development question | Representative assay options | Typical readouts |
|---|---|---|
| Does the protein bind its intended complement partner? | SPR, BLI, ELISA, plate-based binding, competition studies | Affinity/avidity, response, competition, concentration dependence |
| Does it accelerate convertase decay? | Purified convertase decay assays, surface-based decay formats | Residual convertase activity, decay kinetics, IC50/EC50 where appropriate |
| Does it support Factor I cleavage? | C3b or C4b cofactor assays with Factor I and defined cofactor/substrate combinations | iC3b/C3dg or C4 cleavage products, cleavage efficiency, time course |
| Which complement pathways are suppressed? | Classical, alternative and lectin pathway functional assays; CH50/AP50 or tailored hemolysis formats | Percent inhibition, residual pathway activity, concentration-response behavior |
| Does it reduce cascade deposition? | C3b deposition, C4b deposition, C5b-9 deposition | Surface deposition, relative inhibition, pathway- or matrix-dependent effects |
| Does it suppress inflammatory or terminal products? | C3a, C5a, Bb, sC5b-9 or other activation-fragment measurements | Soluble activation products, residual terminal pathway activity |
| Can it protect a biological surface? | Cell-based complement activation, hemolysis, endothelial or project-specific surface models | Cell survival, lysis, deposition, viability, surface-specific protection |
| Is activity retained after engineering or stress? | Pre/post-stress functional comparison combined with SEC, purity and concentration measurements | Potency retention, aggregation/activity relationship, formulation ranking |
Combine pathway-level inhibition with mechanistic assays to distinguish a genuinely improved construct from one that simply expresses better.
The workflow can be compressed for research-protein production or expanded into iterative design-test cycles for therapeutic lead optimization. At each stage, the next experiment is selected from the evidence generated in the previous stage.
Confirm regulator family, complement pathway, intended mechanism, sequence status, material needs, matrix, target surface, comparator, and success criteria.
Build full-length, truncated, variant, multivalent, or fusion constructs; select host, signal peptide, tags, and initial expression strategy.
Express and purify candidate proteins; compare yield, purity, assembly, aggregation, recovery, and basic stability before deeper testing.
Run binding, cofactor/decay, hemolysis, deposition, activation-fragment, or cell-surface assays according to the expected mechanism.
Refine architecture, expression, or formulation; repeat critical assays and prepare the selected material, analytical package, and technical report.
Does the construct express as the expected molecular species and show measurable mechanism-consistent activity?
Does the improved architecture provide a meaningful gain in potency, specificity, stability, exposure strategy, or manufacturability?
Can the lead be reproduced at the required scale without unacceptable loss of purity, activity, or stability?
Soluble regulator programs may prioritize broad pathway inhibition, surface-selective protection, physiologic replacement, disease-variant rescue, or a reagent that enables mechanistic complement studies. The same molecule can require a different assay and production strategy at each stage.
Generate and rank recombinant regulator formats for complement-mediated renal, ocular, inflammatory, ischemia-reperfusion, transplant, hematologic, or other disease programs. Screening can integrate mechanism, serum potency, cell protection, and developability.
Engineer fusions that bring regulatory activity to a tissue, cell, pathogen, biomaterial, or deposited complement fragment. Comparisons can test whether targeting improves local activity without requiring equally broad systemic inhibition.
Compare wild-type proteins with patient-associated or engineered variants to determine whether altered binding, cofactor function, decay acceleration, stability, or expression explains a phenotype.
Produce functional soluble regulators for assay development, pathway controls, complement-depletion/reconstitution experiments, biomaterial testing, or comparative studies of complement activation.
Compare versions of a regulator after sequence changes, expression-host transitions, purification changes, formulation stress, or scale-up to confirm that molecular changes do not compromise complement regulatory activity.
Advance a selected construct into larger-scale production with defined purification and QC, then connect the material to serum, cell-based, or disease-model studies as required by the program.
For teams that need a well-characterized functional regulator without a multi-variant discovery campaign.
For programs comparing architectures, variants, fusions, or domain designs.
For a lead that needs reproducible material and a broader complement activity package.
Use orthogonal component-level assays to verify that the engineered molecule preserves the intended regulatory mechanism.
These original research articles illustrate three practical development strategies: truncating CR1 while retaining complement inhibition, multimerizing minimal Factor H domains, and optimizing Factor H fusion-protein architecture and stability.
Bongoni and colleagues evaluated CSL040, a truncated recombinant human sCR1 format, against full-length soluble CR1 in a renal ischemia-reperfusion model. The study provides a useful example of converting a large natural regulator into a smaller candidate and validating the engineered protein with pathway, tissue, and functional endpoints.
View research via DOI
Kamala and colleagues described a homodimeric minimal Factor H design that combines selected N-terminal regulatory and C-terminal recognition regions with a dimerization module. Their work connects construct architecture, purification, size-exclusion behavior, functional regulation, biodistribution, and longer-term in vivo exposure.
View research via DOI
Shaughnessy and colleagues compared Factor H-derived Fc fusion arrangements and Fc subclasses, examining expression, purification yield, stability, binding, complement-dependent bactericidal activity, and formulation behavior. The study highlights why fusion orientation and scaffold choice should be treated as testable design variables.
View research via DOIProjects may include sCR1/TP10 and CR1-derived fragments, full-length Factor H, FHL-1, mini-FH and Factor H fusion formats, C4BP, Factor I, C1 inhibitor, and project-defined soluble or fusion constructs derived from other complement regulatory proteins. We can work from a published sequence, a client sequence, a disease-associated variant, or a new engineering concept.
Yes. Parallel construct comparison is useful when the goal is to reduce molecular size while preserving regulatory function or to identify the smallest architecture that still provides the required binding, cofactor activity, decay acceleration, or pathway inhibition. Candidates can be evaluated under matched production and assay conditions.
Host selection is based on molecular size, domain architecture, disulfide requirements, multimeric assembly, glycosylation sensitivity, intended scale, and downstream use. Mammalian systems such as HEK293 or CHO are common starting points for complex secreted regulators, while alternative expression strategies can be considered when appropriate.
The panel depends on mechanism and can include target binding by SPR, BLI, or ELISA; Factor I cofactor assays; convertase decay assays; CH50/AP50 or pathway-specific inhibition assays; C3b/C4b/C5b-9 deposition measurements; activation-fragment assays; hemolysis; and cell-based complement protection. Orthogonal assays are often preferable to a single endpoint.
Yes. Depending on the molecule and research objective, we can evaluate Fc or other fusion strategies, dimerization or multivalent formats, targeting modules, linker changes, and additional sequence-level modifications. Each design is tested for both the intended gain and any effect on complement specificity, molecular quality, aggregation, or function.
Yes. Wild-type and variant proteins can be produced and compared side by side. The study can examine expression and molecular quality as well as mechanistic differences in C3b/C4b binding, Factor I-dependent cleavage, pathway inhibition, stability, or surface protection, depending on the protein and variant.
Helpful information includes the regulator family or sequence, intended complement pathway and mechanism, disease or model context, desired construct format, target surface if applicable, material scale, preferred expression host if any, comparator or reference protein, required functional assays, and the decision the final data must support. If the architecture is not yet defined, the project can begin with a design and feasibility phase.
Complement Activity/Function Assay Products
Learn More
Complement Testing Services
Learn More
Complement Therapeutics Featured Products
Learn More
Complement Therapeutics Services Brochure
Learn More
Aptamer Development PLATFORM
Learn More
ComPLETTM Hemolysis Assay Solutions
Learn More